The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

• Published in: Cancer chemotherapy and pharmacology Vol. 65; no. 1; pp. 191 - 195
• Main Authors: DREDGE, K, KINK, J. A, JOHNSON, R. M, BYTHEWAY, I, MARTON, L. J
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 2010
• Subjects: Antineoplastic agents; Biological and medical sciences; Gynecology. Andrology. Obstetrics; Male genital diseases; Medical sciences; Nephrology. Urinary tract diseases; Pharmacology. Drug treatments; Pneumology; Tumors; Tumors of the respiratory system and mediastinum; Tumors of the urinary system; Urinary tract. Prostate gland; Antineoplastic agent; Prostate disease; Lung cancer; Polyamine analog; Preclinical trial; Monoclonal antibody; Bronchopulmonary; Bevacizumab; PG11047; Bronchus disease; Antiangiogenic agent; Male genital diseases; Platinum II Complexes; Lung disease; Polyamine; Urinary system disease; Respiratory disease; Malignant tumor; Biological activity; Cisplatin; Alkylating agent; Vascular endothelium growth factor; Treatment; Analog; Cancer therapy; Models; Prostate cancer; Cancer
• ISSN: 0344-5704; 1432-0843